Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a report issued on Monday morning, Marketbeat.com reports. The brokerage issued an overweight rating on the stock.

Several other brokerages have also recently commented on ATYR. Wells Fargo & Company initiated coverage on Atyr PHARMA in a report on Friday, October 4th. They set an “overweight” rating and a $17.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a report on Tuesday, December 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Trading Down 3.9 %

ATYR opened at $3.74 on Monday. The company’s 50 day simple moving average is $3.34. The company has a market capitalization of $313.94 million, a PE ratio of -3.98 and a beta of 1.08. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.41 and a current ratio of 5.41. Atyr PHARMA has a twelve month low of $1.39 and a twelve month high of $4.22.

Atyr PHARMA (NASDAQ:ATYR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, analysts forecast that Atyr PHARMA will post -0.89 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Atyr PHARMA stock. JPMorgan Chase & Co. boosted its holdings in Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,440 shares of the company’s stock after buying an additional 10,754 shares during the quarter. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About Atyr PHARMA

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.